Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension

Life Sciences

Volumn 118, Issue 2, 2014, Pages 333-339

  Iglarz, Marc ^a   Bossu, Alexandre ^a   Wanner, Daniel ^a   Bortolamiol, Céline ^a   Rey, Markus ^a   Hess, Patrick ^a   Clozel, Martine ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Blood pressure; Endothelin; Pharmacology; Pulmonary hypertension; Rat

Indexed keywords

BLEOMYCIN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL; BLOOD; COMPARATIVE STUDY; DAHL RAT; DISEASE MODEL; DOSE RESPONSE; HYPERTENSION, PULMONARY; RAT; REPRODUCIBILITY;

ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN RECEPTOR ANTAGONISTS; HYPERTENSION, PULMONARY; PYRIMIDINES; RATS; RATS, INBRED DAHL; REPRODUCIBILITY OF RESULTS; SULFONAMIDES;

EID: 85027938315     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.02.018     Document Type: Article

References (19)

1. Bolli, M.H., Boss, C., Binkert, C., Buchmann, S., Bur, D., Hess, P., et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55 (2012), 7849–7861.
2. Brockway, B., Mills, P., Azar, S., A new method for continuous chronic measurement and recording of blood pressure, heart rate, and activity in the rat via radiotelemetry. Clin Exp Hypertens A 13 (1991), 885–895.
3. Clozel, M., Breu, V., Gray, G.A., Kalina, B., Löffler, B.M., Burri, K., et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270 (1994), 228–235.
4. Emoto, N., Raharjo, S.B., Isaka, D., Masuda, S., Adiarto, S., Jeng, A.Y., et al. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 45 (2005), 1145–1152.
5. Frelin, C., Guedin, D., Why are circulating concentrations of endothelin-1 so low?. Cardiovasc Res 28 (1994), 1613–1622.
6. Gatfield, J., Mueller Grandjean, C., Sasse, T., Clozel, M., Nayler, O., Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One, 7, 2012, e47662.
7. Iglarz, M., Binkert, C., Morrison, K., Fischli, W., Gatfield, J., Treiber, A., et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327 (2008), 736–745.
8. Iglarz, M., Landskroner, K., Rey, M., Wanner, D., Hess, P., Clozel, M., Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension. Am J Respir Crit Care Med, 183, 2011, A6445.
9. McLaughlin, V.V., Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 20 (2011), 262–269.
10. Mutsaers, S.E., Foster, M.L., Chambers, R.C., Laurent, G.J., McAnulty, R.J., Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol 18 (1998), 611–619.
11. Park, S.H., Saleh, D., Giaid, A., Michel, R.P., Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156 (1997), 600–608.
12. Pulido, T., Adzerikho, I., Channick, R.N., Delcroix, M., Galie, N., Ghofrani, H.A., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369 (2013), 809–818.
13. Quaschning, T., d'Uscio, L.V., Shaw, S., Viswambharan, H., Ruschitzka, F.T., Luscher, T.F., Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension. Nephrol Dial Transplant 16 (2001), 1176–1182.
14. Rey, M., Weber, E.W., Hess, P.D., Simultaneous pulmonary and systemic blood pressure and ECG Interval measurement in conscious, freely moving rats. J Am Assoc Lab Anim Sci 51 (2012), 231–238.
15. Ryan, J., Bloch, K., Archer, S.L., Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. Int J Clin Pract Suppl, 2011, 15–34.
16. Schiffrin, E.L., A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 38:Suppl. 2 (2001), S3–S6.
17. Swinney, D.C., Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001–2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 6 (2006), 461–478.
18. Voelkel, N.F., Gomez-Arroyo, J., Abbate, A., Bogaard, H.J., Nicolls, M.R., Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 40 (2012), 1555–1565.
19. Williams, J.H. Jr., Bodell, P., Hosseini, S., Tran, H., Baldwin, K.M., Haemodynamic sequelae of pulmonary fibrosis following intratracheal bleomycin in rats. Cardiovasc Res 26 (1992), 401–408.